HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Nature Communications"
DOI: 10.1038/s41467-025-65599-x
Abstract: Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which… read more here.
Keywords: breast cancer; her2dx; chemotherapy; her2 positive ... See more keywords
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djac227
Abstract: In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown.… read more here.
Keywords: her2dx; erbb2 mrna; advanced her2; breast cancer ... See more keywords